{"id":"mesalazine-tablets","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"3-8","effect":"Nausea"},{"rate":"2-5","effect":"Rash"},{"rate":"<1","effect":"Nephrotoxicity (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mesalazine (5-aminosalicylic acid) is a topical anti-inflammatory agent that acts locally in the gastrointestinal tract. It inhibits the production of inflammatory mediators including prostaglandins and leukotrienes, and may also have antioxidant properties. The drug is used to treat and maintain remission of inflammatory bowel disease by reducing mucosal inflammation.","oneSentence":"Mesalazine reduces inflammation in the colon and rectum by inhibiting prostaglandin and leukotriene production, thereby suppressing inflammatory mediators.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:52.191Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ulcerative colitis (induction and maintenance of remission)"},{"name":"Crohn's disease (colonic involvement)"},{"name":"Inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT04095663","phase":"NA","title":"Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2019-10-01","conditions":"Diverticulitis","enrollment":255},{"nctId":"NCT05684484","phase":"PHASE4","title":"Role of Roflumilast in Ulcerative Colitis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-02-01","conditions":"Ulcerative Colitis","enrollment":52},{"nctId":"NCT04133194","phase":"PHASE4","title":"Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis","status":"UNKNOWN","sponsor":"Flemming Bendtsen","startDate":"2019-11-28","conditions":"Ulcerative Colitis","enrollment":200},{"nctId":"NCT03445624","phase":"","title":"Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-07-01","conditions":"Inflammatory Bowel Diseases","enrollment":60},{"nctId":"NCT05626166","phase":"PHASE3","title":"the Efficacy and Safety of Diosmin in Patients With Ulcerative Colitis","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-12-15","conditions":"Ulcerative Colitis","enrollment":60},{"nctId":"NCT03441893","phase":"PHASE1, PHASE2","title":"Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis","status":"UNKNOWN","sponsor":"Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan","startDate":"2015-01-01","conditions":"Ulcerative Colitis, Ulcerative Colitis Exacerbation, Protozoan Infections","enrollment":300},{"nctId":"NCT02769494","phase":"PHASE3","title":"The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer","status":"WITHDRAWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2016-03","conditions":"Crohn's Disease, Oral Ulcer","enrollment":""},{"nctId":"NCT01130844","phase":"PHASE1","title":"Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis","status":"COMPLETED","sponsor":"Shire","startDate":"2010-10-08","conditions":"Ulcerative Colitis","enrollment":52},{"nctId":"NCT00446849","phase":"PHASE4","title":"Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Shire","startDate":"2007-05-01","conditions":"Ulcerative Colitis","enrollment":290},{"nctId":"NCT00545103","phase":"PHASE3","title":"Prevention of Recurrence of Diverticulitis","status":"COMPLETED","sponsor":"Shire","startDate":"2007-12-06","conditions":"Diverticulitis","enrollment":592},{"nctId":"NCT01124149","phase":"PHASE4","title":"Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis","status":"COMPLETED","sponsor":"Shire","startDate":"2010-06-29","conditions":"Ulcerative Colitis","enrollment":759},{"nctId":"NCT02093663","phase":"PHASE3","title":"Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis","status":"COMPLETED","sponsor":"Shire","startDate":"2014-12-12","conditions":"Ulcerative Colitis","enrollment":107},{"nctId":"NCT01412372","phase":"PHASE3","title":"The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study","status":"COMPLETED","sponsor":"University of Utah","startDate":"2010-06","conditions":"Irritable Bowel Syndrome","enrollment":61},{"nctId":"NCT03399903","phase":"PHASE1, PHASE2","title":"Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection","status":"COMPLETED","sponsor":"AIDS Healthcare Foundation","startDate":"2017-05-01","conditions":"HIV-1-infection, Gut Inflammation","enrollment":47},{"nctId":"NCT00708656","phase":"PHASE3","title":"The Colitis Once Daily Asacol Study","status":"COMPLETED","sponsor":"Cardiff and Vale University Health Board","startDate":"2006-10","conditions":"Ulcerative Colitis","enrollment":213},{"nctId":"NCT00679432","phase":"PHASE3","title":"(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-06","conditions":"Ulcerative Colitis","enrollment":510},{"nctId":"NCT00408174","phase":"PHASE3","title":"Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2006-05","conditions":"Inflammatory Bowel Disease, Ulcerative Colitis","enrollment":400},{"nctId":"NCT00269438","phase":"PHASE3","title":"New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2005-12","conditions":"Ulcerative Colitis","enrollment":225},{"nctId":"NCT01532648","phase":"PHASE3","title":"Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2012-01-27","conditions":"Ulcerative Colitis","enrollment":510},{"nctId":"NCT03917095","phase":"NA","title":"The Safety and Efficacy of TET Enema in the Treatment of UC","status":"UNKNOWN","sponsor":"The Second Hospital of Nanjing Medical University","startDate":"2019-05-15","conditions":"Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate","enrollment":75},{"nctId":"NCT03070574","phase":"PHASE2","title":"Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome","status":"TERMINATED","sponsor":"Christoph Gasche","startDate":"2017-11-24","conditions":"Colorectal Cancer","enrollment":8},{"nctId":"NCT02368717","phase":"PHASE3","title":"An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2015-03","conditions":"Ulcerative Colitis","enrollment":281},{"nctId":"NCT01059344","phase":"PHASE3","title":"Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Tillotts Pharma AG","startDate":"2009-11","conditions":"Ulcerative Colitis","enrollment":281},{"nctId":"NCT01999400","phase":"NA","title":"Correlation of Mesalamine Pharmacokinetics With Local Availability","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2012-04","conditions":"Local Drug Concentration in Gastrointestinal Tract","enrollment":30},{"nctId":"NCT01699438","phase":"PHASE2","title":"Mesalazine Treatment in IBS (The MIBS Study)","status":"COMPLETED","sponsor":"Hans Törnblom","startDate":"2012-04","conditions":"Irritable Bowel Syndrome","enrollment":211},{"nctId":"NCT01514240","phase":"PHASE3","title":"Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-02","conditions":"Crohn's Disease","enrollment":123},{"nctId":"NCT00603733","phase":"PHASE3","title":"Canadian Active & Maintenance Modified Pentasa Study","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2007-10","conditions":"Active Ulcerative Colitis, Remission of Ulcerative Colitis","enrollment":288},{"nctId":"NCT00073021","phase":"PHASE3","title":"Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2000-09","conditions":"Ulcerative Colitis","enrollment":386},{"nctId":"NCT02306798","phase":"PHASE1","title":"TP0502-B-Pharmaco-Scintigraphic-Study","status":"COMPLETED","sponsor":"Tillotts Pharma AG","startDate":"2013-09","conditions":"Ulcerative Colitis","enrollment":9},{"nctId":"NCT02306785","phase":"PHASE1","title":"TP0502-Pharmaco-Scintigraphic-Study and Amendment","status":"COMPLETED","sponsor":"Tillotts Pharma AG","startDate":"2012-10","conditions":"Ulcerative Colitis","enrollment":26},{"nctId":"NCT02306772","phase":"PHASE1","title":"TP0501 - Pharmaco-Scintigraphic-Study","status":"COMPLETED","sponsor":"Tillotts Pharma AG","startDate":"2011-12","conditions":"Ulcerative Colitis","enrollment":18},{"nctId":"NCT01831323","phase":"","title":"Evaluation of the Metabolome in Diverticular Disease","status":"UNKNOWN","sponsor":"S.Eugenio Hospital","startDate":"2012-12","conditions":"Simple Diverticular Disease","enrollment":40},{"nctId":"NCT00505778","phase":"PHASE3","title":"A Comparison of Once a Day Dose Compared to 2 Doses/Day","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2007-07","conditions":"Ulcerative Colitis","enrollment":1027},{"nctId":"NCT00554099","phase":"PHASE2","title":"Asacol Acute Diverticulitis(DIVA)Study","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2007-11","conditions":"Diverticulitis","enrollment":117},{"nctId":"NCT00254618","phase":"PHASE1","title":"A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis.","status":"TERMINATED","sponsor":"Warner Chilcott","startDate":"2005-10","conditions":"Ulcerative Colitis","enrollment":34},{"nctId":"NCT00350415","phase":"PHASE3","title":"A Double Blind Study for the Treatment of Acute Ulcerative Colitis","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2006-06","conditions":"Ulcerative Colitis","enrollment":772},{"nctId":"NCT00751699","phase":"PHASE1","title":"Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2007-03","conditions":"Healthy","enrollment":37},{"nctId":"NCT01257399","phase":"PHASE3","title":"Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase","status":"COMPLETED","sponsor":"Tillotts Pharma AG","startDate":"2010-11","conditions":"Ulcerative Colitis in Remission","enrollment":251},{"nctId":"NCT01257386","phase":"PHASE3","title":"Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Tillotts Pharma AG","startDate":"2010-11","conditions":"Active Ulcerative Colitis","enrollment":251},{"nctId":"NCT00946946","phase":"PHASE3","title":"Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine","status":"COMPLETED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2002-02","conditions":"Crohn's Disease","enrollment":78},{"nctId":"NCT01004185","phase":"PHASE3","title":"Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis","status":"TERMINATED","sponsor":"Warner Chilcott","startDate":"2009-10","conditions":"Ulcerative Colitis","enrollment":39},{"nctId":"NCT00713310","phase":"PHASE3","title":"Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2008-12","conditions":"Ulcerative Colitis","enrollment":83},{"nctId":"NCT01534754","phase":"PHASE4","title":"Mesalazine and/or Lactobacillus Casei in the Diverticular Disease of the Colon","status":"COMPLETED","sponsor":"Hospital Cristo Re","startDate":"2009-01","conditions":"Diverticular Disease of the Colon","enrollment":250},{"nctId":"NCT00577473","phase":"PHASE3","title":"Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2001-02","conditions":"Ulcerative Colitis","enrollment":301},{"nctId":"NCT00225810","phase":"PHASE4","title":"A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2005-10","conditions":"Crohn's Disease","enrollment":50},{"nctId":"NCT01104753","phase":"","title":"A Study of Pentasa in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2009-09","conditions":"Ulcerative Colitis","enrollment":338},{"nctId":"NCT01045018","phase":"PHASE3","title":"A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis","status":"COMPLETED","sponsor":"EMET Pharmaceuticals, LLC","startDate":"2008-01","conditions":"Mild to Moderate Ulcerative Colitis","enrollment":""},{"nctId":"NCT00194818","phase":"PHASE4","title":"Asacol Dosing Study for Active Ulcerative Colitis","status":"COMPLETED","sponsor":"University of Washington","startDate":"2003-06","conditions":"Ulcerative Colitis","enrollment":7},{"nctId":"NCT00092508","phase":"PHASE3","title":"CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-05","conditions":"Ulcerative Colitis","enrollment":1725}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Mesalazine tablets","genericName":"Mesalazine tablets","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mesalazine reduces inflammation in the colon and rectum by inhibiting prostaglandin and leukotriene production, thereby suppressing inflammatory mediators. Used for Ulcerative colitis (induction and maintenance of remission), Crohn's disease (colonic involvement), Inflammatory bowel disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}